NYSE:TEVA - Teva Pharmaceutical Industries Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $10.71
Forecasted Upside: 38.97 %
Number of Analysts: 8
Breakdown:
1 Sell Ratings
5 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$7.71 As of 07/5/2022 01:00 AM ET

▼ -0.18 (-2.28%)

1 month | 3 months | 12 months

Get New Teva Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for TEVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEVA

^$10.71

▲ +38.97% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Teva Pharmaceutical Industries in the last 3 months. The average price target is $10.71, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 38.97% upside from the last price of $7.71.

Current Consensus is Hold

The current consensus among 8 investment analysts is to hold stock in Teva Pharmaceutical Industries. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
12 hold ratings
3 sell ratings

Ratings as of

1/11/2021

0 strong buy ratings
2 buy ratings
11 hold ratings
1 sell ratings

Ratings as of

4/11/2021

0 strong buy ratings
1 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

7/10/2021

0 strong buy ratings
0 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/8/2021

0 strong buy ratings
0 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/6/2022

0 strong buy ratings
2 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/6/2022

0 strong buy ratings
2 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

6/5/2022

0 strong buy ratings
2 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

7/5/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/13/2022	UBS Group	Initiated Coverage	Neutral	$10.00	Low
5/17/2022	Bank of America	Upgrade	Underperform ➝ Neutral	$9.00	N/A
5/4/2022	Piper Sandler	Downgrade	Neutral ➝ Underweight	$11.00 ➝ $7.00	Low
4/5/2022	Barclays	Upgrade	Equal Weight ➝ Overweight	$11.00 ➝ $13.00	N/A
3/25/2022	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$11.00	Medium
2/18/2022	Barclays	Lower Price Target	Equal Weight	$13.00 ➝ $11.00	Medium
1/27/2022	Argus	Downgrade	Buy ➝ Hold		Medium
10/28/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		High
7/29/2021	Raymond James	Lower Price Target	Outperform	$15.00 ➝ $14.00	Medium
7/29/2021	Wells Fargo & Company	Lower Price Target	Equal Weight	$12.00 ➝ $11.00	Medium
5/10/2021	UBS Group	Reiterated Rating	Buy ➝ Neutral	$15.00 ➝ $11.00	N/A
5/4/2021	UBS Group	Downgrade	Buy ➝ Neutral	$15.00 ➝ $11.00	High
3/14/2021	JPMorgan Chase & Co.	Reiterated Rating	Hold	$10.00	Medium
12/28/2020	Raymond James	Reiterated Rating	Buy		N/A
11/24/2020	Oppenheimer	Initiated Coverage	Market Perform		Low
11/6/2020	BMO Capital Markets	Lower Price Target	Market Perform	$13.00 ➝ $11.00	High
10/23/2020	Raymond James	Reiterated Rating	Buy		Low
10/13/2020	Argus	Lower Price Target	Average ➝ Buy	$14.00 ➝ $11.00	Low
9/14/2020	Raymond James	Reiterated Rating	Buy		Low
8/26/2020	Bank of America	Reiterated Rating	Sell	$8.00	Low
8/6/2020	SVB Leerink	Boost Price Target	Market Perform	$13.00 ➝ $14.00	Medium
8/6/2020	Barclays	Upgrade	Underweight ➝ Equal Weight	$10.00 ➝ $13.00	Medium
7/27/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$12.00	Low
6/1/2020	SunTrust Banks	Upgrade	Hold ➝ Buy	$11.00 ➝ $16.00	High
5/11/2020	UBS Group	Boost Price Target	Buy	$12.00 ➝ $15.00	Medium
5/8/2020	Cantor Fitzgerald	Reiterated Rating	Neutral		Low
5/8/2020	SVB Leerink	Boost Price Target	Market Perform	$11.00 ➝ $12.00	Low
5/8/2020	Bank of America	Reiterated Rating	Underperform	$7.00 ➝ $8.00	Low
4/24/2020	Citigroup	Initiated Coverage	Neutral		Low
4/17/2020	Barclays	Reiterated Rating	Sell	$9.00	Low
4/15/2020	Piper Sandler	Lower Price Target	Neutral	$10.00 ➝ $8.00	Low
4/6/2020	UBS Group	Upgrade	Neutral ➝ Buy	$14.00 ➝ $12.00	High
4/2/2020	Morgan Stanley	Lower Price Target	Underweight	$13.00 ➝ $8.00	Medium
3/23/2020	Bank of America	Lower Price Target	Underperform	$11.00 ➝ $7.00	Low
3/5/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$10.00 ➝ $12.00	Low
2/24/2020	Edward Jones	Downgrade	Hold ➝ Sell		High
2/18/2020	Argus	Boost Price Target	Buy	$10.00 ➝ $15.00	Low
2/17/2020	UBS Group	Boost Price Target	Neutral	$8.00 ➝ $14.00	Medium
2/14/2020	Morgan Stanley	Boost Price Target	Underweight	$8.00 ➝ $13.00	High
2/13/2020	Bank of America	Boost Price Target	Underperform	$8.00 ➝ $11.00	High
2/13/2020	SunTrust Banks	Boost Price Target	Hold	$9.00 ➝ $13.00	Medium
2/13/2020	Oppenheimer	Boost Price Target	Outperform	$12.00 ➝ $16.00	High
2/12/2020	Cantor Fitzgerald	Boost Price Target	In-Line ➝ Neutral	$9.00 ➝ $15.00	Low
2/12/2020	Cfra	Boost Price Target	Hold	$11.00 ➝ $13.00	Low
1/22/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$8.00 ➝ $10.00	Medium
1/3/2020	Bank of America	Upgrade	Underperform ➝ Buy		High
11/12/2019	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$8.00	Medium
10/16/2019	Gabelli	Upgrade	Hold ➝ Buy		High
9/30/2019	Wells Fargo & Company	Lower Price Target	Market Perform	$17.00 ➝ $8.00	Low
9/12/2019	Guggenheim	Initiated Coverage	Neutral		Low
9/6/2019	JPMorgan Chase & Co.	Lower Price Target	Underweight	$9.00 ➝ $7.00	Low
8/16/2019	UBS Group	Set Price Target	Hold	$8.00	High
8/9/2019	BMO Capital Markets	Lower Price Target	Market Perform	$11.00 ➝ $9.00	N/A
8/8/2019	Royal Bank of Canada	Reiterated Rating	Hold	$10.00	High
8/8/2019	SunTrust Banks	Lower Price Target	Hold	$7.00	Medium
8/8/2019	Raymond James	Lower Price Target	Outperform	$22.00 ➝ $15.00	Medium
8/7/2019	Cowen	Set Price Target	Hold	$9.00	Low
7/19/2019	Wolfe Research	Initiated Coverage	Peer Perform ➝ Peer Perform	$9.00	Low
7/15/2019	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$16.00 ➝ $6.00	High
7/10/2019	Credit Suisse Group	Reiterated Rating	Neutral		Low
7/5/2019	Argus	Upgrade	Hold ➝ Buy	$12.00	High
6/18/2019	Sanford C. Bernstein	Lower Price Target	Market Perform	$17.00 ➝ $11.00	Medium
6/17/2019	Mizuho	Set Price Target	Hold	$11.00	Medium
6/17/2019	Citigroup	Set Price Target	Buy	$23.00 ➝ $13.00	Low
6/12/2019	Oppenheimer	Set Price Target	Buy	$12.00	High
6/12/2019	Cantor Fitzgerald	Lower Price Target	Neutral	$16.00 ➝ $9.00	Low
6/11/2019	Barclays	Initiated Coverage	Underweight ➝ Underweight	$8.00	Medium
6/3/2019	CIBC	Upgrade	Market Perform ➝ Outperform	$12.00	Medium
6/3/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$12.00	Low
5/30/2019	Bank of America	Downgrade	Buy ➝ Underperform	$19.00 ➝ $9.00	High
5/28/2019	Wells Fargo & Company	Set Price Target	Hold	$17.00	Medium
5/28/2019	UBS Group	Downgrade	Buy ➝ Neutral	$22.00 ➝ $12.00	High
5/10/2019	Wells Fargo & Company	Reiterated Rating	Hold		High
5/9/2019	Wells Fargo & Company	Lower Price Target	Market Perform	$18.00 ➝ $17.00	Low
5/3/2019	Royal Bank of Canada	Set Price Target	Hold	$19.00	Low
5/3/2019	BMO Capital Markets	Set Price Target	Hold	$17.00	Low
5/3/2019	Morgan Stanley	Set Price Target	Hold	$16.00	Low
5/3/2019	Cantor Fitzgerald	Boost Price Target	Positive ➝ Neutral	$16.00 ➝ $25.00	Medium
5/2/2019	Maxim Group	Reiterated Rating	Hold		Low
4/11/2019	Citigroup	Lower Price Target	Buy	$27.00 ➝ $23.00	Low
4/3/2019	Wells Fargo & Company	Lower Price Target	Market Perform ➝ Market Perform	$20.00 ➝ $18.00	Low
3/28/2019	BMO Capital Markets	Initiated Coverage	Market Perform	$18.00	Medium
3/19/2019	SunTrust Banks	Initiated Coverage	Hold ➝ Hold	$17.00	Low
3/7/2019	UBS Group	Initiated Coverage	Buy	$22.00	Medium
3/6/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$17.00	High
2/20/2019	Mizuho	Downgrade	Buy ➝ Neutral	$25.00 ➝ $18.00	Medium
2/14/2019	Credit Suisse Group	Lower Price Target	Neutral ➝ Neutral	$26.00 ➝ $20.00	Medium
2/14/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$22.00	Medium
2/14/2019	Maxim Group	Reiterated Rating	Hold		Medium
2/14/2019	Wells Fargo & Company	Reiterated Rating	Hold	$24.00 ➝ $20.00	Medium
2/11/2019	Oppenheimer	Reiterated Rating	Hold		Medium
2/5/2019	Credit Suisse Group	Reiterated Rating	Hold	$26.00	High
2/5/2019	HSBC	Set Price Target	Sell	$12.00	High
2/5/2019	Bank of America	Reiterated Rating	Buy	$24.00	Low
1/23/2019	Piper Jaffray Companies	Upgrade	Underweight ➝ Neutral	$15.00 ➝ $16.00	Low
1/23/2019	UBS Group	Upgrade	Neutral ➝ Buy		Low
1/3/2019	Bank of America	Upgrade	Underperform ➝ Buy	$16.12	High
12/13/2018	Credit Suisse Group	Set Price Target	Hold	$26.00	Medium
11/7/2018	Oppenheimer	Reiterated Rating	Hold		Medium
11/5/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$20.00 ➝ $27.00	Low
11/2/2018	Bank of America	Boost Price Target	Underperform ➝ Underperform	$19.00 ➝ $20.00	Low
11/2/2018	Royal Bank of Canada	Set Price Target	Hold	$22.00	Low
11/2/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
11/1/2018	Maxim Group	Reiterated Rating	Hold		High
11/1/2018	Oppenheimer	Reiterated Rating	Hold		High
10/17/2018	Wells Fargo & Company	Set Price Target	Hold	$23.00	Low
10/17/2018	Oppenheimer	Reiterated Rating	Hold		Medium
10/14/2018	Credit Suisse Group	Set Price Target	Hold	$26.00	Medium
10/1/2018	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$30.00	High
10/1/2018	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$16.00 ➝ $24.00	High
9/27/2018	Wells Fargo & Company	Set Price Target	Hold	$23.00	Low
9/27/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$25.00	High
9/21/2018	CIBC	Reiterated Rating	Market Perform ➝ Market Perform		Low
9/20/2018	Oppenheimer	Reiterated Rating	Hold		Medium
9/17/2018	Mizuho	Boost Price Target	Buy	$28.00 ➝ $29.00	High
9/17/2018	Credit Suisse Group	Set Price Target	Hold	$23.00 ➝ $26.00	High
9/17/2018	Wells Fargo & Company	Set Price Target	Hold	$23.00	High
9/17/2018	BTIG Research	Upgrade	Sell ➝ Neutral		High
9/14/2018	Cantor Fitzgerald	Set Price Target	Hold	$25.00	Low
9/7/2018	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$25.00 ➝ $23.00	Low
8/24/2018	Mizuho	Reiterated Rating	Buy	$28.00	Low
8/16/2018	Mizuho	Reiterated Rating	Buy	$28.00	High
8/16/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$25.00	High
8/3/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$19.00 ➝ $20.00	Medium
8/3/2018	Jefferies Financial Group	Reiterated Rating	Hold	$21.00	Medium
8/2/2018	Barclays	Set Price Target	Equal Weight ➝ Hold	$20.00 ➝ $23.00	Medium
8/2/2018	Cantor Fitzgerald	Set Price Target	Hold	$25.00	Medium
8/2/2018	Oppenheimer	Reiterated Rating	Hold		Medium
8/2/2018	Mizuho	Reiterated Rating	Buy	$27.00	High
8/2/2018	Wells Fargo & Company	Set Price Target	Hold	$23.00	Medium
7/31/2018	Royal Bank of Canada	Reiterated Rating	Hold	$19.00	Medium
7/19/2018	Cantor Fitzgerald	Set Price Target	Hold	$25.00	Medium
7/13/2018	Cantor Fitzgerald	Set Price Target	Neutral ➝ Hold	$18.00 ➝ $25.00	Low
6/27/2018	Citigroup	Boost Price Target	Buy	$25.00 ➝ $27.00	Medium
6/25/2018	The Goldman Sachs Group	Boost Price Target	Buy	$25.00 ➝ $28.00	Medium
6/18/2018	Wells Fargo & Company	Upgrade	Underperform ➝ Market Perform		Medium
5/31/2018	Citigroup	Set Price Target	Buy ➝ Buy	$24.00 ➝ $25.00	Low
5/24/2018	Barclays	Set Price Target	Equal Weight ➝ Hold	$13.00 ➝ $20.00	Medium
5/17/2018	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Low
5/14/2018	Credit Suisse Group	Set Price Target	Buy	$23.00	Low
5/7/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/7/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Hold	$18.00	Low
5/3/2018	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Low
5/3/2018	Maxim Group	Reiterated Rating	Hold		Low
4/22/2018	Wells Fargo & Company	Set Price Target	Sell	$17.00	Low
4/20/2018	Mizuho	Reiterated Rating	Buy	$27.00	Low
4/4/2018	Credit Suisse Group	Set Price Target	Buy	$23.00	High
3/26/2018	Royal Bank of Canada	Reiterated Rating	Hold	$16.00	Low
3/20/2018	Jefferies Financial Group	Initiated Coverage	Hold ➝ Hold	$19.00	Medium
3/1/2018	Maxim Group	Reiterated Rating	Hold		Medium
2/13/2018	Wells Fargo & Company	Reiterated Rating	Sell		Medium
2/11/2018	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$20.00 ➝ $23.00	Medium
2/9/2018	Bank of America	Lower Price Target	Underperform ➝ Underperform	$17.00 ➝ $16.00	Low
2/9/2018	SVB Leerink	Lower Price Target	Underweight ➝ Underperform	$17.00 ➝ $16.00	High
2/9/2018	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold ➝ Hold	$20.00 ➝ $18.00	Medium
2/9/2018	Gabelli	Downgrade	Buy ➝ Hold	$19.00	Medium
2/9/2018	Piper Jaffray Companies	Downgrade	Neutral ➝ Underweight	$11.00	Medium
2/9/2018	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$18.00	Medium
2/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Medium
2/8/2018	Oppenheimer	Reiterated Rating	Hold		Medium
2/8/2018	Maxim Group	Reiterated Rating	Hold		Medium
2/2/2018	BTIG Research	Downgrade	Neutral ➝ Sell	$17.00	Low
1/30/2018	Royal Bank of Canada	Set Price Target	Sell	$13.00	Low
1/26/2018	SVB Leerink	Boost Price Target	Underperform	$15.00 ➝ $17.00	Low
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive ➝ Positive	$22.00 ➝ $24.00	Medium
1/24/2018	Royal Bank of Canada	Set Price Target	Sell	$13.00	Low
1/23/2018	Oppenheimer	Reiterated Rating	Hold		Low
1/22/2018	Credit Suisse Group	Set Price Target	Hold	$20.00	Low
1/22/2018	Maxim Group	Reiterated Rating	Hold		Low
1/22/2018	Wells Fargo & Company	Reiterated Rating	Sell		Low
1/18/2018	BTIG Research	Downgrade	Buy ➝ Neutral	$24.00	Low
1/11/2018	The Goldman Sachs Group	Boost Price Target	Buy	$20.00 ➝ $25.00	High
1/9/2018	Mizuho	Upgrade	Neutral ➝ Buy	$19.12 ➝ $23.00	N/A
1/5/2018	Wells Fargo & Company	Downgrade	Market Perform ➝ Underperform	$19.58 ➝ $17.00	Low
1/4/2018	Citigroup	Upgrade	Neutral ➝ Buy	$24.00	Low
1/3/2018	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Medium
1/2/2018	SVB Leerink	Initiated Coverage	Underperform ➝ Underperform	$15.00	Medium
12/28/2017	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Low
12/18/2017	UBS Group	Set Price Target	Hold	$12.00 ➝ $20.00	Low
12/15/2017	Royal Bank of Canada	Set Price Target	Sell	$13.00	Low
12/15/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$20.00	Medium
12/15/2017	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$8.00 ➝ $20.00	Medium
12/15/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	$18.00	Medium
12/15/2017	BTIG Research	Boost Price Target		$20.00	High
12/15/2017	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$20.00	High
12/14/2017	Wells Fargo & Company	Reiterated Rating	Hold		High
12/14/2017	Piper Jaffray Companies	Set Price Target	Hold	$16.00	High
12/14/2017	Oppenheimer	Reiterated Rating	Hold		High
12/14/2017	Cantor Fitzgerald	Set Price Target	Hold	$10.00	High
12/12/2017	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$16.00	High
11/29/2017	Royal Bank of Canada	Set Price Target	Sell	$11.00	Low
11/29/2017	Mizuho	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $16.00	Medium
11/28/2017	BTIG Research	Set Price Target	Buy	$16.00	Low
11/27/2017	Cantor Fitzgerald	Set Price Target	Hold	$10.00	High
11/25/2017	Wells Fargo & Company	Reiterated Rating	Hold		High
11/17/2017	Mizuho	Reiterated Rating	Neutral ➝ Neutral	$15.00 ➝ $12.00	N/A
11/14/2017	Cantor Fitzgerald	Set Price Target	Hold	$10.00	N/A
11/13/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$11.48 ➝ $11.00	N/A
11/12/2017	Oppenheimer	Reiterated Rating	Hold		N/A
11/6/2017	Susquehanna Bancshares	Lower Price Target	Positive ➝ Positive	$20.00 ➝ $14.00	N/A
11/6/2017	Credit Suisse Group	Reiterated Rating	Underperform	$14.00 ➝ $8.00	N/A
11/5/2017	Royal Bank of Canada	Boost Price Target	Underperform	$8.00 ➝ $13.00	N/A
11/3/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$12.00	N/A
11/3/2017	Morgan Stanley	Lower Price Target	Underweight	$14.00 ➝ $7.00	N/A
11/3/2017	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$14.00	N/A
11/2/2017	Wells Fargo & Company	Downgrade	Market Perform	$17.00 ➝ $11.36	N/A
10/30/2017	Mizuho	Reiterated Rating	Hold	$15.00	N/A
10/30/2017	Royal Bank of Canada	Reiterated Rating	Underperform ➝ Underperform	$15.00 ➝ $13.00	N/A
10/26/2017	Cantor Fitzgerald	Set Price Target	Hold	$17.00	N/A
10/25/2017	Evercore ISI	Set Price Target	Buy	$38.00	N/A
10/20/2017	Royal Bank of Canada	Set Price Target	Sell	$15.00	N/A
10/20/2017	Barclays	Set Price Target	Hold	$21.00 ➝ $19.00	N/A
10/19/2017	Cantor Fitzgerald	Set Price Target	Hold	$17.00	N/A
10/6/2017	Piper Jaffray Companies	Set Price Target	Hold	$23.00	N/A
10/5/2017	Morgan Stanley	Set Price Target	Underweight	$16.00 ➝ $15.00	N/A
10/5/2017	Wells Fargo & Company	Reiterated Rating	Market Perform		N/A
10/4/2017	Wells Fargo & Company	Set Price Target	Hold	$20.00	N/A
10/4/2017	Cowen	Reiterated Rating	Market Perform	$30.00 ➝ $18.00	N/A
10/4/2017	Maxim Group	Reiterated Rating	Hold		N/A
10/4/2017	Oppenheimer	Reiterated Rating	Hold		Medium
10/4/2017	Mizuho	Reiterated Rating	Hold	$16.00	Medium
10/4/2017	Barclays	Set Price Target	Equal Weight	$23.00 ➝ $21.00	Medium
10/4/2017	BTIG Research	Reiterated Rating	Buy	$24.00	Medium
10/2/2017	Cantor Fitzgerald	Set Price Target	Hold	$17.00	Low
9/21/2017	Sanford C. Bernstein	Lower Price Target	Mkt Perform ➝ Market Perform	$28.00 ➝ $20.00	Low
9/18/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$17.00	Low
9/18/2017	Royal Bank of Canada	Lower Price Target	Underperform	$21.00 ➝ $15.00	High
9/14/2017	Maxim Group	Reiterated Rating	Hold	$15.50	Low
9/14/2017	UBS Group	Reiterated Rating	Neutral	$19.00	Low
9/13/2017	Gabelli	Reiterated Rating	Buy		Low
9/12/2017	Jefferies Financial Group	Lower Price Target	Hold	$21.00 ➝ $18.50	High
9/11/2017	Oppenheimer	Reiterated Rating	Hold		Low
9/11/2017	Cantor Fitzgerald	Set Price Target	Hold	$27.00 ➝ $17.00	High
9/11/2017	BTIG Research	Upgrade	Neutral ➝ Buy	$24.00	High
9/6/2017	JMP Securities	Boost Price Target	Underperform	$13.00 ➝ $14.00	Low
9/5/2017	Royal Bank of Canada	Reiterated Rating	Underperform		Medium
9/5/2017	Cantor Fitzgerald	Reiterated Rating	Neutral	$27.00	High
8/31/2017	The Goldman Sachs Group	Reiterated Rating	Neutral	$28.00 ➝ $21.00	Low
8/30/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$27.00	Low
8/23/2017	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$25.00 ➝ $13.00	Medium
8/22/2017	Mizuho	Reiterated Rating	Neutral	$30.00 ➝ $16.00	Low
8/16/2017	Citigroup	Downgrade	Buy ➝ Neutral	$32.00 ➝ $19.00	Medium
8/9/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$43.00 ➝ $28.00	High
8/9/2017	Jefferies Financial Group	Reiterated Rating	Hold	$33.00 ➝ $26.00	Medium
8/9/2017	Cantor Fitzgerald	Reiterated Rating	Neutral	$31.00 ➝ $27.00	High
8/9/2017	Credit Suisse Group	Reiterated Rating	Outperform	$39.00	High
8/7/2017	Barclays	Lower Price Target	Equal Weight	$38.00 ➝ $23.00	High
8/4/2017	Piper Jaffray Companies	Reiterated Rating	Neutral	$28.00 ➝ $23.00	High
8/4/2017	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$42.00 ➝ $28.00	High
8/4/2017	Maxim Group	Reiterated Rating	Hold	$35.00	High
8/4/2017	Cowen	Downgrade	Outperform ➝ Market Perform	$50.00 ➝ $30.00	High
8/4/2017	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$39.00 ➝ $25.00	High
8/4/2017	Royal Bank of Canada	Downgrade	Outperform ➝ Underperform	$37.00 ➝ $21.00	N/A
8/3/2017	Cantor Fitzgerald	Set Price Target	Hold	$27.00	High
8/3/2017	CIBC	Reiterated Rating	Outperform ➝ Market Perform		High
8/3/2017	UBS Group	Downgrade	Outperform ➝ Market Perform		High
8/3/2017	Credit Suisse Group	Set Price Target	Buy	$39.00	High
8/3/2017	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$41.00	High
8/2/2017	Mizuho	Reiterated Rating	Hold	$30.00	High
7/25/2017	Jefferies Financial Group	Reiterated Rating	Neutral ➝ Hold		Low
7/18/2017	Oppenheimer	Reiterated Rating	Outperform	$41.00	Low
7/17/2017	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$38.00 ➝ $37.00	Low
7/13/2017	Maxim Group	Reiterated Rating	Hold	$35.00	High

(Data available from 7/6/2017 forward)

News Sentiment Rating

-0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/7/2021

4 very positive mentions
20 positive mentions
5 negative mentions
4 very negative mentions

Mentions as of

1/6/2022

3 very positive mentions
0 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

2/5/2022

5 very positive mentions
11 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

3/7/2022

7 very positive mentions
16 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

4/6/2022

6 very positive mentions
8 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

5/6/2022

8 very positive mentions
15 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

6/5/2022

1 very positive mentions
6 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

7/5/2022

Current Sentiment

Recent Stories by Sentiment

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Today's Range

Now: $7.71

$7.55

$7.76

50 Day Range

MA: $8.26

$7.38

$9.52

52 Week Range

Now: $7.71

$7.23

$10.50

Volume

7,611,371 shs

Average Volume

9,384,305 shs

Market Capitalization

$8.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?: The following sell-side analysts have issued research reports on Teva Pharmaceutical Industries in the last year: Argus, Bank of America Co., Barclays PLC, Piper Sandler, Raymond James, Sanford C. Bernstein, StockNews.com, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for TEVA.
What is the current price target for Teva Pharmaceutical Industries?: 0 Wall Street analysts have set twelve-month price targets for Teva Pharmaceutical Industries in the last year. Their average twelve-month price target is $10.71, suggesting a possible upside of 39.0%.
View the latest price targets for TEVA.
What is the current consensus analyst rating for Teva Pharmaceutical Industries?: Teva Pharmaceutical Industries currently has 1 sell rating, 5 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TEVA, but not buy more shares or sell existing shares.
View the latest ratings for TEVA.
What other companies compete with Teva Pharmaceutical Industries?: Other companies that are similar to Teva Pharmaceutical Industries include Astellas Pharma, Royalty Pharma, MERCK Kommanditgesellschaft auf Aktien, Genmab A/S, Takeda Pharmaceutical, Genmab A/S, BeiGene, Horizon Therapeutics Public, Catalent, Alnylam Pharmaceuticals, UCB, Shiseido, BioMarin Pharmaceutical, Ono Pharmaceutical and Viatris. Learn More about companies similar to Teva Pharmaceutical Industries.
How do I contact Teva Pharmaceutical Industries' investor relations team?: Teva Pharmaceutical Industries' physical mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company's listed phone number is (723) 914-8213 and its investor relations email address is [email protected] The official website for Teva Pharmaceutical Industries is www.tevapharm.com. Learn More about contacing Teva Pharmaceutical Industries investor relations.

NYSE:TEVA - Teva Pharmaceutical Industries Stock Price Target and Predictions

Analyst Price Target for TEVA

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

-0.30 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?

What is the current price target for Teva Pharmaceutical Industries?

What is the current consensus analyst rating for Teva Pharmaceutical Industries?

What other companies compete with Teva Pharmaceutical Industries?

How do I contact Teva Pharmaceutical Industries' investor relations team?